Objective To evaluate the association of state medical and recreational cannabis laws and commercialization with rates of psychosis-related health care utilization.
Main Outcomes and Measures Outcomes were rates of psychosis-related diagnoses and prescribed antipsychotics.
Conclusions and Relevance In this retrospective cohort study of commercial and Medicare Advantage claims data, state medical and recreational cannabis policies were not associated with a statistically significant increase in rates of psychosis-related health outcomes. As states continue to introduce new cannabis policies, continued evaluation of psychosis as a potential consequence of state cannabis legalization may be informative.
